FibroGen Inc (NAS:FGEN)
$ 1.19 0.01 (0.85%) Market Cap: 118.38 Mil Enterprise Value: 89.74 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 58/100

FibroGen Inc at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 06:20PM GMT
Release Date Price: $17.2 (+1.30%)
Paul Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst

I'm Paul Choi, and I cover the small and mid-cap biotechnology sector here at Goldman Sachs. It's my pleasure to welcome Enrique Conterno, CEO of FibroGen. We'll do a little Q&A with Enrique here. The team -- management team is also available here in the audience. If along the way, if anybody in the audience has a question, please feel free to raise your hand, and we'll try and get a mic to you. Also, if you want to ask a question anonymously, you can e-mail it to us and we'll read it over the webcast here.

So Enrique, maybe I'll let you start with maybe some high-level comments and just kind of the year ahead for FibroGen. You've had from a mix of good news and bad news earlier this year with regard to the clinical front, but you also obviously have some potentially thesis changing events coming up here ahead. So could you maybe just talk about maybe at a high level, how you're thinking about FibroGen in 2023.

Enrique A. Conterno
FibroGen, Inc. - CEO & Director

Thank

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot